Dimerix's ACTION3 Study Reaches Milestone with Positive Statistical Review

Dimerix Celebrates Key Statistical Validation in ACTION3 Study

Dimerix Limited (ASX: DXB) has announced a major achievement in its ongoing ACTION3 Phase 3 clinical study, which seeks to evaluate the efficacy of DMX-200, a novel therapy aimed at treating kidney disease caused by Focal Segmental Glomerulosclerosis (FSGS). The recent external blinded review of the ACTION3 data has confirmed that the study maintains a statistically significant power of greater than 90% to demonstrate a treatment effect on the primary endpoint of proteinuria reduction.

This milestone means that if DMX-200 continues to effectively reduce protein levels in the urine among trial participants, there is a very high probability (over 90%) that the study will show statistically significant results at its conclusion. This is excellent news for Dimerix and its investors as it marks a step closer towards potentially gaining regulatory approval for DMX-200 based on these encouraging results.

Study Context and Recruitment Details

Currently, the ACTION3 trial comprises a full recruitment of 333 adult patients, with the final participant anticipated to complete their treatment regimen by March 2028. In addition, Dimerix is actively recruiting pediatric patients aged 12-17 years for an independent cohort, which presents an opportunity to broaden the application of DMX-200 to younger age groups.

The completion of a formal futility analysis in March 2024 demonstrated that DMX-200 was outperforming the placebo in proteinuria reduction at that time. This data has been corroborated by an independent review board, which has conducted seven separate evaluations and found no safety concerns that warrant any changes in the protocol.

Evolving Guidelines for FSGS Treatment

In conjunction with the blinded review, Dimerix has consulted with its commercial partners to reassess the landscape of FSGS treatment and the criteria for regulatory approval since the initiation of the ACTION3 study in 2022. The PARASOL working group findings have reinforced proteinuria as a solid candidate for a primary endpoint. The FDA has also validated proteinuria as an appropriate measure for regulatory approval processes.

Recent developments show that proteinuria endpoints require smaller sample sizes and exhibit less variability compared to estimated Glomerular Filtration Rate (eGFR) assessments, which could reduce risks associated with obtaining FDA marketing approvals in the U.S. This strategic focus on proteinuria ultimately strengthens the potential for Dimerix to succeed in getting traditional approval for DMX-200 while minimizing risks involved with accelerated approval routes.

Future Implications for Patients and Dimerix

Dr. David Fuller, Chief Medical Officer at Dimerix, emphasizes the significance of focusing on proteinuria as the primary endpoint: “This review provides clarity on the regulatory pathway for DMX-200, significantly reducing clinical and commercial risks and enhancing the prospects for successful marketing approval.”

With a likely fast-tracked process for regulatory approval, many hope DMX-200 could soon provide a critical treatment avenue for the over 40,000 Americans suffering from FSGS, many of whom currently have no approved medications tailored to their condition.

As the ACTION3 trial progresses, Dimerix reaffirms its commitment to advancing this vital research while maintaining open communication with stakeholders and partners in various territories not yet sanctioned.

The results of this study could pave the way for Dimerix to offer significant therapeutic options for individuals impacted by FSGS, marking a promising leap in the biopharmaceutical industry towards more effective kidney disease treatments.